The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy: Single-center, Non-inferiority, Open-label Randomized Trial
| Registry | NCT05645198, acronym OOZFIX |
|---|---|
| Status | Unknown |
| Phase | Phase 4 |
| Study type | Interventional; randomized, parallel, masking: none, prevention |
| Enrollment | 180 (Estimated) |
| Sponsor | Bucheon St. Mary's Hospital (Other) |
| Conditions | Stomach Neoplasm |
| Interventions | Oozfix, Greenplast (Drug) |
| Dates | start 2022-10-26, primary completion 2024-12-31 (estimated), completion 2025-01-31 (estimated), first posted 2022-12-09, last updated 2022-12-09 |
| Locations | 1 site in South Korea |
Related Papers Related Patents Related Grants Related Experts
All trials for Stomach Neoplasm All trials of Oozfix All trials of Greenplast
Although the technique of radical gastrectomy had been advanced, postoperative complication can occur in 13\~25% of patient after radical gastrectomy. Pancreatic fistula and postoperative bleeding was reported as 2\~30% and 1\~2%, respectively. These complications often result fatal clinical course, so localized fibrin agent has been widely used at postoperative surgical bed after radical gastrectomy.
Recently, natural origin polysaccharide-based carboxymetyl starch was approved as localized coagulative, no well-designed report was adressed in gastric cancer surgery field. This agent can formate physical barrier after application, thus can prevent microbleeding or pancreatic fistula after gastrectomy. THIS study is single-center, non-inferiority, open-label randomized trial that evaluates the effect of carboxymetyl starch (Oozfix) on preventing postoperative complication after gastrectomy.
Although the technique of radical gastrectomy had been advanced, postoperative complication can occur in 13\~25% of patient after radical gastrectomy. Pancreatic fistula and postoperative bleeding was reported as 2\~30% and 1\~2%, respectively. These complications often result fatal clinical course, so localized fibrin agent has been widely used at postoperative surgical bed after radical gastrectomy.
Recently, natural origin polysaccharide-based carboxymetyl starch was approved as localized coagulative, no well-designed report was adressed in gastric cancer surgery field. This agent can formate physical barrier after application, thus can prevent microbleeding or pancreatic fistula after gastrectomy. THIS study is single-center, non-inferiority, open-label randomized trial that evaluates the effect of carboxymetyl starch (Oozfix) on preventing postoperative complication after gastrectomy.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Oozfix | Experimental | Drug: Oozfix | Arm with oozfix after gastrectomy |
| Greenplast | Active comparator | Drug: Greenplast | Arm with greenplast after gastrectomy |
Sex: All, ages: 19 Years to 80 Years
Inclusion Criteria: 1. Gastric adenocarcinoma patient who underwent radical gastrectomy at Bucheon St. Mary's Hospital 2. Patient's Age is above 19 and less than 80 3. ECOG performance score : 0\~2 Exclusion Criteria: 1. Patient who underwent emergent gastrectomy 2. Patient who requires palliative gastrectomy due to advanced or metastatic carcinoma 3. Patient who requires operation due to other malignancy other than adenocrcinoma 4. Patient who underwent emergent gastrectomy or pancreatectomy before this study 5. Patient who underwent chemoradiation 6. Patient who took anticoagulants or with coagulopathy
| Facility | City | Country | Status |
|---|---|---|---|
| BucheonStMarys | Bucheon-si | South Korea | Recruiting |